Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Autor: Gregorio Barilà, Angela Grassi, HeeJin Cheon, Antonella Teramo, Giulia Calabretto, Jasmanet Chahal, Cristina Vicenzetto, Julia Almeida, Bryna C. Shemo, Min Shi, Vanessa Rebecca Gasparini, Noemi Munoz-Garcia, Cédric Pastoret, Hideyuki Nakazawa, Kazuo Oshimi, Lubomir Sokol, Fumihiro Ishida, Thierry Lamy, Alberto Orfao, William G. Morice, Thomas P. Loughran, Gianpietro Semenzato, Renato Zambello
Přispěvatelé: Venetian Institute Molecular Medicine (VIMM), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Zhejiang University, CHU Pontchaillou [Rennes], Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Blood
Blood, 2023, 141 (9), pp.1036-1046. ⟨10.1182/blood.2021013489⟩
ISSN: 0006-4971
1528-0020
DOI: 10.1182/blood.2021013489⟩
Popis: Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in ∼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαβ cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P < .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2− cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαβ cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαβ LGLL.
Databáze: OpenAIRE
Externí odkaz: